Dementia Risk Reduced by GLP-1 Agonists

In summary, patients with type 2 diabetes who use GLP-1 agonists, such as Ozempic, have a lower incidence of dementia. A 30% reduced dementia risk was observed in comparison to sulfonylureas and a 23% lower risk was shown in comparison to DPP-4 inhibitors, according to studies that tracked over 88,000 people for up to ten years.

Physicians might use these findings as guidance when choosing drugs for elderly patients with diabetes. To validate these findings, more randomized trials are necessary.

Important Details:

1. Considerable Risk Reduction: When compared to sulfonylureas, GLP-1 agonists reduce the risk of dementia by 30%.
2. Study Scope: For a maximum of ten years, nearly 88,000 older persons with type 2 diabetes were monitored.
3. Clinical Implications: The results can assist physicians in selecting the best medications for people with diabetes.

The Karolinska Institute

GLP-1 agonist-treated type 2 diabetics have a lower chance of dementia, per a recent Karolinska Institutet study that was published in the journal eClinicalMedicine.

GLP-1 agonists and GLP-1 analogs are medications that help regulate blood sugar, encourage weight loss, and protect the heart. As a result, they are being used more and more to treat type 2 diabetes and obesity.

The risk of dementia is higher in people with type 2 diabetes, and it has been suggested that more recent diabetic medications, such as DPP-4 inhibitors and GLP-1 agonists, may provide some protection against dementia.

Researchers tracked over 88,000 older people with type 2 diabetes for up to ten years in the new register-based study. Target trial emulation, a research design that mimics a randomized clinical trial, was employed to examine the relationship between three diabetic medications (DPP-4 inhibitors, sulfonylureas, and GLP-1 agonists) and dementia risk.

can aid medical professionals in making better judgments

Researchers discovered that patients on GLP-1 agonists had a 23% lower risk of dementia development compared to those taking DPP-4 inhibitors, and a 30% lower risk compared to those taking sulfonylureas.

“This is important because it can help doctors make better decisions about which medicines to use for older patients with type 2 diabetes,” says Bowen Tang, a Ph.D. student in Sara Hägg’s research group at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.

“However, proper randomized trials are needed to establish with certainty that GLP-1 agonists reduce the risk of dementia.”

For more information: Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study, eClinicalMedicine, DOI:https://doi.org/10.1016/j.eclinm.2024.102689